论文部分内容阅读
背景与目的贝伐单抗是针对VEGF的重组人源化单克隆抗体,2006年10月被美国FDA批准联合泰素卡铂化疗方案用于晚期非鳞型非小细胞肺癌的一线治疗。本文应用贝伐单抗联合泰素卡铂化疗方案,观察中国晚期肺癌患者应用贝伐单抗治疗的安全性。方法贝伐单抗应用15 mg/kg,化疗第1 d静点,以后每3周重复;联合化疗方案为紫杉醇:175 mg/m~2,d_1,卡铂:AUC=6,d_1,每3周重复。化疗应用4-6周期,贝伐单抗每3周应用直至病情进展。治疗过程中据NCI CTC 3.0版本评价不良反应级别、记录分析不良反应发生时间、治疗及转归。结果13例患者发生3级鼻出血1例、4级血栓栓塞1例,较常见不良反应为1或2级的鼻出血、咯血、高血压、蛋白尿等,均程度较轻可以耐受。结论贝伐单抗联合紫杉醇卡铂方案化疗一线治疗晚期肺癌多数患者耐受良好。
Background and Objective Bevacizumab is a recombinant humanized monoclonal antibody against VEGF. In October 2006, it was approved by the U.S. FDA for the first-line treatment of advanced non-squamous non-small cell lung cancer with the combination of paclitaxel and platinum chemotherapy. In this paper, bevacizumab combined with paclitaxel chemotherapy regimen to observe the application of bevacizumab in patients with advanced lung cancer in China. Methods Bevacizumab was given intravenously at a dose of 15 mg / kg once a day for 1 day and repeated every 3 weeks thereafter. The combined chemotherapy regimen was paclitaxel: 175 mg / m 2, d_1, carboplatin: AUC = 6, d_1 Weeks repeated. 4-6 cycles of chemotherapy, bevacizumab every 3 weeks until disease progression. According to the NCI CTC 3.0 version during treatment, the grade of adverse reactions was recorded, the time of occurrence of adverse reactions, treatment and prognosis were recorded. Results Thirteen patients had grade 3 epistaxis in 1 case and grade 4 thromboembolism in 1 case. The most common adverse reactions were grade 1 or 2 epistaxis, hemoptysis, hypertension and proteinuria, which were both tolerable to light. Conclusion Bevacizumab combined with paclitaxel carboplatin chemotherapy in the first-line treatment of advanced lung cancer in most patients well tolerated.